OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of no…
Biotechnology
FR, Nantes [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -100.00 | -10.09 | 0.00 | |
| Graham Fair Price | 100.00 | 3.66 | 0.00 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | 100.00 | 3.88 | 0.00 | |
| Price/Cash Flow | -100.00 | -10.99 | 0.00 | |
| Prices/Earnings | -100.00 | -1.98 | 0.00 | |
| Price/Sales | 100.00 | 101.80 | 0.00 | |
| Price/FCF | -100.00 | -10.99 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 100.00 | 1.00 | 0.00 | |
| Operating Margin | -100.00 | -15.13 | 0.00 | |
| ROA | n.A. | -0.14 | n.A. | |
| ROE | n.A. | -0.49 | n.A. | |
| ROIC | n.A. | -0.15 | n.A. | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 0.00 | 0.00 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | 0.00 | 0.00 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 938.42 | 100.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.66 | 0.65 | -1.22 | |
| Quick Ratio | 0.81 | 1.48 | 82.14 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 1.10 | 100.00 | |
| Cash | 0.00 | 0.90 | 100.00 | |
| Capex | 0.00 | < 0.005 | -100.00 | |
| Free Cash Flow | 0.00 | -0.39 | -100.00 | |
| Revenue | 0.00 | 0.04 | 100.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Weak